Patents by Inventor Carl-Johan Dalsgaard

Carl-Johan Dalsgaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12213961
    Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.
    Type: Grant
    Filed: November 17, 2023
    Date of Patent: February 4, 2025
    Assignee: VICORE PHARMA AB
    Inventors: Carl-Johan Dalsgaard, Rohit Batta
  • Patent number: 12128029
    Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.
    Type: Grant
    Filed: December 20, 2023
    Date of Patent: October 29, 2024
    Assignee: VICORE PHARMA AB
    Inventors: Carl-Johan Dalsgaard, Rohit Batta
  • Publication number: 20240207232
    Abstract: Aspects of the present disclosure are directed to methods of treating a patient diagnosed with an interstitial lung disease (ILD), comprising administering a pharmaceutical drug for treating the ILD in a treatment regimen effective to treat fibrosis, inflammation, and/or vasculopathy, and in conjunction with the administration of the pharmaceutical drug, engaging in a self-directed digital therapeutic program that treats patient anxiety relating to the administration of the pharmaceutical drug, wherein the engaging in the self-directed digital therapeutic program is effective to increase adherence to the treatment regimen.
    Type: Application
    Filed: December 22, 2023
    Publication date: June 27, 2024
    Applicants: Vicore Pharma AB, Alex Therapeutics AB
    Inventors: Johan RAUD, Carl-Johan DALSGAARD, Jessica SHULL, Kimmy BOLKE, Oliver FLEETWOOD
  • Publication number: 20240207231
    Abstract: Aspects of the present disclosure are directed to methods of treating a patient diagnosed with an interstitial lung disease (ILD), comprising administering a pharmaceutical drug for treating the ILD in a treatment regimen effective to treat fibrosis, inflammation, and/or vasculopathy, and in conjunction with the administration of the pharmaceutical drug, engaging in a self-directed digital therapeutic program that treats patient anxiety relating to the administration of the pharmaceutical drug, wherein the engaging in the self-directed digital therapeutic program is effective to increase adherence to the treatment regimen.
    Type: Application
    Filed: July 14, 2023
    Publication date: June 27, 2024
    Applicants: Vicore Pharma AB, Alex Therapeutics AB
    Inventors: Johan RAUD, Carl-Johan Dalsgaard, Jessica Shull, Kimmy Bolke, Oliver Fleetwood
  • Publication number: 20240207230
    Abstract: Aspects of the present disclosure are directed to methods of treating an interstitial lung disease (ILD) in a patient, comprising administering a pharmaceutical treatment that is useful in the therapy of an ILD; and, in conjunction with the administration of the pharmaceutical treatment, engaging in a digital therapeutic program that delivers cognitive behavioural therapy for the treatment of anxiety which the patient identifies as leading to possible exacerbations of the symptoms of the ILD. Suitable pharmaceutical treatments include those that are useful in the therapy of an ILD, including pharmaceutical treatments that are in some way disease-modifying and/or capable of altering the course or the pathology of the ILD or at least slowing its progression, such as such as an antifibrotic agent, an immunomodulatory imide drug (IMID) or an angiotensin II type 2 receptor agonist (ATRAG).
    Type: Application
    Filed: February 24, 2023
    Publication date: June 27, 2024
    Applicants: Vicore Pharma AB, Alex Therapeutics AB
    Inventors: Johan RAUD, Carl-Johan DALSGAARD, Jessica SHULL, Kimmy BOLKE, Oliver FLEETWOOD
  • Publication number: 20240122902
    Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.
    Type: Application
    Filed: December 20, 2023
    Publication date: April 18, 2024
    Inventors: Carl-Johan DALSGAARD, Rohit BATTA
  • Publication number: 20240108604
    Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.
    Type: Application
    Filed: November 17, 2023
    Publication date: April 4, 2024
    Inventors: Carl-Johan DALSGAARD, Rohit BATTA
  • Patent number: 11819494
    Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.
    Type: Grant
    Filed: February 25, 2022
    Date of Patent: November 21, 2023
    Assignee: VICORE PHARMA AB
    Inventors: Carl-Johan Dalsgaard, Rohit Batta
  • Publication number: 20230248698
    Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.
    Type: Application
    Filed: February 25, 2022
    Publication date: August 10, 2023
    Inventors: Carl-Johan DALSGAARD, Rohit BATTA
  • Publication number: 20220233480
    Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviates symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality.
    Type: Application
    Filed: January 20, 2022
    Publication date: July 28, 2022
    Inventors: Carl-Johan DALSGAARD, Johan RAUD, Rohit BATTA
  • Publication number: 20210401807
    Abstract: According to the invention, there is provided a pharmaceutical composition suitable for administration to the lung, which composition comprises a plurality of amorphous nanoporous silica particles, in which N-butyloxycarbonyl-3-(4-imidazol-1-yl-methylphenyl)-5-iso-butylthiophene-2-sulfonamide or a pharmaceutically-acceptable salt thereof is loaded into the pores of said silica particles, and wherein the silica particles have: (a) a mass median aerodynamic diameter that is between about 0.1 ?m and about 10 ?m; and (b) a geometric standard deviation that is less than about 4. Such compositions find particular utility in the treatment of an interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis, which diseases may be treated with such compositions for example by way of pulmonary administration.
    Type: Application
    Filed: November 6, 2019
    Publication date: December 30, 2021
    Inventors: Carl-Johan DALSGAARD, Adam FEILER, Chunfang ZHOU, Paulina PASZKIEWICZ, Xin XIA
  • Publication number: 20210386712
    Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutyl-thiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality.
    Type: Application
    Filed: August 27, 2021
    Publication date: December 16, 2021
    Inventors: Carl-Johan Dalsgaard, Johan Raud, Rohit Batta
  • Publication number: 20210290596
    Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality.
    Type: Application
    Filed: December 7, 2020
    Publication date: September 23, 2021
    Inventors: Carl-Johan Dalsgaard, Johan Raud, Rohit Batta
  • Patent number: 11123329
    Abstract: There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: September 21, 2021
    Assignee: VICORE PHARMA AB
    Inventors: Carl-Johan Dalsgaard, Johan Raud, Rohit Batta
  • Publication number: 20210236425
    Abstract: According to the invention, there is provided a pharmaceutical composition suitable for administration to the lung, which composition comprises a plurality of amorphous nanoporous silica particles, in which one or more immunomodulatory imide drug is loaded into the pores of said particles, and wherein the silica particles have: (a) a mass median aerodynamic diameter that is between about 0.1 ?m and about 10 ?m; and (b) a geometric standard deviation that is less than about 4, for use in the treatment of an interstitial lung disease by pulmonary administration. Preferred immunomodulatory imide drugs include thalidomide. Interstitial lung diseases that may be mentioned include idiopathic pulmonary fibrosis and sarcoidosis.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 5, 2021
    Inventors: Carl-Johan DALSGAARD, Adam FEILER, Chunfang ZHOU, Paulina PASZKIEWICZ, Xin XIA
  • Publication number: 20170112837
    Abstract: According to the invention there is provided a method for the treatment of airway hyperresponsiveness, which method comprises the administration of pemirolast, or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment. Suitable lower doses of pemirolast are least about 110 mg per day.
    Type: Application
    Filed: April 22, 2016
    Publication date: April 27, 2017
    Inventors: Johan RAUD, Carl-Johan DALSGAARD, Goran TORNLING
  • Publication number: 20170112838
    Abstract: According to the invention there is provided a method for the treatment of airway hyperresponsiveness, which method comprises the administration of pemirolast, or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment. Suitable lower doses of pemirolast are least about 110 mg per day.
    Type: Application
    Filed: August 12, 2016
    Publication date: April 27, 2017
    Inventors: Johan Raud, Carl-Johan Dalsgaard, Göran Tornling
  • Patent number: 9492454
    Abstract: According to the invention there is provided pemirolast, or a pharmaceutically acceptable salt thereof, for use in the therapeutic treatment of asthma, such as an acute asthma attack. Suitable lower doses of pemirolast are least about 110 mg per day.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: November 15, 2016
    Assignee: RSPR Pharma AB
    Inventors: Johan Raud, Carl-Johan Dalsgaard, Jesper Säfholm
  • Publication number: 20160310493
    Abstract: According to the invention there is provided pemirolast, or a pharmaceutically acceptable salt thereof, for use in the therapeutic treatment of asthma, such as an acute asthma attack. Suitable lower doses of pemirolast are least about 110 mg per day.
    Type: Application
    Filed: April 22, 2016
    Publication date: October 27, 2016
    Inventors: Johan RAUD, Carl-Johan DALSGAARD, Jesper SÄFHOLM
  • Publication number: 20160243122
    Abstract: According to the invention there is provided pemirolast, or a pharmaceutically acceptable salt thereof, for use in the therapeutic treatment of asthma, such as an acute asthma attack. Suitable lower doses of pemirolast are least about 110 mg per day.
    Type: Application
    Filed: October 23, 2015
    Publication date: August 25, 2016
    Inventors: Johan RAUD, Carl-Johan DALSGAARD, Jesper SÄFHOLM